INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 426m ago
HOUSE PTR25m ago
SEC 13F25m ago
ROBINHOOD CHAIN25m ago
Public company

ELVNEnliven Therapeutics, Inc.

CIK 0001672619

EDGAR filingsOpen in network
Disclosed transactions54
Buys / sells0 / 34
Max Insider Score26
Connections6with evidence

ELVN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$12K
5,000 sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Collins Helen LouiseCHIEF MEDICAL OFFICER · Mar 27, 2026
  • ← Insider ofevidence
    Hohl BenjaminCHIEF FINANCIAL OFFICER · Dec 23, 2025
  • ← Insider ofevidence
    Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · Nov 21, 2025
0
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
$89K
6,018 sh
Oct 19, 2026
Oct 21, 2026
traded Oct 19, 2026
+2d
SEC FORM 4

Evidence

0
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
5,000 sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

10
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$192K
5,000 sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

10
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$232K
6,018 sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

0
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,018 sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

3
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$12K
5,000 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

13
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$146K
2,916 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

13
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$94K
1,844 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

2
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
3,982 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

13
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$177K
3,535 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

13
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$111K
2,194 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

6
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$15K
289 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

0
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,982 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

6
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$12K
240 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

0
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
5,000 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

11
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$270K
4,630 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

4
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$82K
1,388 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

14
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$59K
1,379 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

18
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$149K
3,401 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

14
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$55K
1,238 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

9
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,018 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

9
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$15K
6,018 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

0
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
5,000 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

8
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$117K
2,441 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

8
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$115K
2,419 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

1
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$6,413
140 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

3
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$12K
5,000 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

7
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
40.0K sh
Mar 25, 2026Mar 27, 2026
traded Mar 25, 2026
+2dSEC FORM 4

Evidence

26
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.40M
40.0K sh
Mar 25, 2026Mar 27, 2026
traded Mar 25, 2026
+2dSEC FORM 4

Evidence

14
CL
Collins Helen LouiseCHIEF MEDICAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$99K
40.0K sh
Mar 25, 2026Mar 27, 2026
traded Mar 25, 2026
+2dSEC FORM 4

Evidence

8
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Grant or award
A—
112.5K sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

8
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Grant or award
A—
20.0K sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

8
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Grant or award
A—
120.0K sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

8
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Grant or award
A—
18.8K sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

1
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$145K
5,000 sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

9
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$390K
14.5K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

6
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$145K
5,491 sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

6
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$6,926
243 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

19
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.34M
48.1K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$151K
7,500 sh
Jan 8, 2026Jan 12, 2026
traded Jan 8, 2026
+4dSEC FORM 4

Evidence

19
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.46M
50.0K sh
Jan 9, 2026Jan 12, 2026
traded Jan 9, 2026
+3dSEC FORM 4

Evidence

12
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$842K
33.8K sh
Jan 8, 2026Jan 12, 2026
traded Jan 8, 2026
+4dSEC FORM 4

Evidence

15
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.03M
41.2K sh
Jan 9, 2026Jan 12, 2026
traded Jan 9, 2026
+3dSEC FORM 4

Evidence

9
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$84K
5,000 sh
Dec 19, 2025Dec 23, 2025
traded Dec 19, 2025
+4dSEC FORM 4

Evidence

13
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise
M—
13.0K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC FORM 4

Evidence

21
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise
M$32K
13.0K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC FORM 4

Evidence

9
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$103K
4,958 sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

6
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$37K
1,705 sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

21
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$268K
12.0K sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

15
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$11K
492 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

21
KS
Kintz SamuelDirector, PRESIDENT AND CEO
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$273K
12.5K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

24
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$105K
6,054 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

21
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$11K
613 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Kintz SamuelDirector, PRESIDENT AND CEO · Nov 19, 2025
  • ← Insider ofevidence
    Patel AnishCHIEF OPERATING OFFICER · Nov 12, 2025